Dijon, France April 25, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company developing products for emergency situations harnessing its proprietary needle-free auto-injectors technology platform ZENEO®, reports its audited financial results for the year ending December 31, 2023. These results are now available on the Company’s website.

Key financial information as of December 31, 2023

Crossject’s financial results for the year ending December 31, 2023 have now been fully audited with a minor change of -0.17 M€ compared to the previous report, released on March 29 and available here.

All reports relating to financials for the year 2023 will be available on the Crossject website from April 30 and are also presented in the appendices below.

The table below summarizes our income statement for the years ending 31 December 2023 and 2022:

€ thousands, as of 31 December 2023 2022
Operating income 12 826 9 718
Operating expenses -24 626 -23 005
Purchase of raw material and supplies -1 595 -498
Other purchases and external expenses -8 869 -8 116
Personal expenses -7 713 -7 424
Taxes and duties -267 -176
Depreciation, amortisation and provision -5 688 -6 358
Other expenses -494 -433
Operating profit/loss -11 800 -13 288
Financial income/expense -497 -319
Exceptional income/expense 791 228
Corporate tax 2 867 2 222
Net profit/loss -8 638 -11 157

About Crossject

Crossject SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharma company developing products for emergencies harnessing its proprietary needle-free auto-injector technology ZENEO. It is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it has a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company’s award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing. The Company’s other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks.

For further information, please contact:

Investors Natasha DrapeauCohesion Bureau+41 76 823 75 27natasha.drapeau@cohesionbureau.com MediaSophie BaumontCohesion Bureau+33 6 27 74 74 49sophie.baumont@cohesionbureau.com  

APPENDICES

INCOME STATEMENT (in K€) 31/12/2023 31/12/2022 VARIATION
 
Revenue 145 954 -809
Stored production 591 348 243
Capitalised production 3 594 6 104 -2 510
Subsidies 133 5 128
Reversals of provisions and transfers of expenses 2 632 445 2 187
Other income 6 231 1 861 4 370
Operating income 13 326 9 717 3 609
Purchases of raw materials and other supplies 1 625 1 002 623
Change in inventory (raw materials and other supplies) -29 -505 476
Other purchases and external expenses 8 869 8 115 754
Taxes and duties 267 177 90
Personnel expenses 7 714 7 425 289
Depreciation, amortisation 4 504 5 263 -759
Other provisions 1 682 1 095 587
Other expenses 494 433 61
Operating expenses 25 126 23 005 2 121
Operating profit/loss -11 800 -13 288 1 488
Financial income/expense -497 -319 -178
Exceptional income/expense 791 228 563
Research Tax Credit 2 867 2 222 645
Net profit/loss -8 638 -11 157 2 519
BALANCE SHEET - LIABILITIES (in k€) 31/12/2023 31/12/2022 VARIATION
CAPITAUX PROPRES
Capital 3 676 3 652 24
Share premium 785 18 312 -17 527
Retained earnings -1 757 -8 786 7 029
Profit/loss for the year -8 638 -11 157 2 519
Investment subsidies 665 665 0
TOTAL SHAREHOLDERS' EUITY -5 269 2 686 -7 955
Conditional advances 7 060 7 476 -416
Provision for contingencies and charges 694 1 420 -726
BORROWINGS AND DEBT
Bonds 18 355 -337
Loans 16 171 11 048 5 123
Miscellaneous 2 732 2 722 10
Debts - Trade payables 4 323 3 523 800
Total tax ans social security liabilities 2 149 1 833 316
Debts on fixed assets 82 1 764 -1 682
Deffered income 681 32 649
TOTAL DEBT 26 156 21 277 4 879
TOTAL EQUITY AND LIABILITIES 28 641 32 859 -4 218
BALANCE SHEET - ASSETS (in K€) 31/12/2023 31/12/2022 VARIATION
FIXED ASSETS
R&D 10 730 10 691 39
Patent and Trademarks 0 0 0
Other intangible assets 0 0 0
Land 14 89 -75
Property, plant and equipment 2 736 5 085 -2 350
Assets under construction 2 942 2 492 450
Financial assets 1 544 672 872
TOTAL FIXED ASSETS 17 966 19 029 -1 064
CURRENT ASSETS
Raw materials, other supplies 1 649 1 416 232,6
Work in process 1 485 588 897
Advances ans prepayments received on order in progress 187 345 -158
Trade and related receivables 2 079 726 1353
State and other reveivables 2 512 2 450 62
Marketable securities 0 0 0
Available cash 2 304 7 769 -5465
Prepaid / deferred expenses 459 536 -76,6
TOTAL CURRENT ASSETS 10 675 13 830 -3 155
TOTAL ASSETS 28 641 32 859 -4 219
BALANCE SHEET - LIABILITIES (in k€) 31/12/2023 31/12/2022 VARIATION
CAPITAUX PROPRES
Capital 3 676 3 652 24
Share premium 785 18 312 -17 527
Regulated reserve 0 0 0
Retained earnings -1 757 -8 786 7 029
Profit/loss for the year -8 638 -11 157 2 519
Investment subsidies 665 665 0
TOTAL SHAREHOLDERS' EUITY -5 269 2 686 -7 955
Conditional advances 7 060 7 476 -416
Provision for contingencies and charges 694 1 420 -726
BORROWINGS AND DEBT
Bonds 18 355 -337
Loans 16 171 11 048 5 123
Miscellaneous 2 732 2 722 10
Debts - Trade payables 4 323 3 523 800
Total tax ans social security liabilities 2 149 1 833 316
Debts on fixed assets 82 1 764 -1 682
Deffered income 681 32 649
TOTAL DEBT 26 156 21 277 4 879
TOTAL EQUITY AND LIABILITIES 28 641 32 859 -4 218
CASH FLOW STATEMENT (IN K€) 31/12/2023 31/12/2022    
         
         
Net profit / loss - 8 638 - 11 157    
       Depreciation, amortisation and provision 3 091 5 705    
       Capital gains on disposal, net of tax               54 1    
       Other income and expenses calculated - 28 - 28    
Cashflow from operations - 5 521 - 5 479    
Change in working capital requirements - 680 399    
(1) Net cash generated by / (used in) operating activities - 6 201 - 5 080    
Acquisition of fixed assets - 6 403 - 6 778    
Cession d'immobilisation 3 767                0        
(2) Net cash generated by / (used in) investing activities - 2 636 - 6 778    
     Capital increase 13 4 089    
Exercice of warrants 333 3 003    
Loans 8 090 4 000    
Repayment of borrowings - 3 396 - 969    
Debts on fixed assets - 1 682 - 483    
(3) Net cash generated by / (used in) financing activities           3 358 9 640    
         
Change in cash and cash equivalents (1)+(2)+(3) - 5 479 - 2 218    
         
Opening Cash position 7 770 9 983    
Closing Cash position 2 291 7 770    

Attachment

  • Press release FY 2023 Full Financials 24042024 EN
Crossject (EU:ALCJ)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Crossject Charts.
Crossject (EU:ALCJ)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Crossject Charts.